Qld start-up Thrombostat raises $800,000 in VC, grants
24 July, 2003 by Pete YoungBrisbane start-up company Thrombostat has attracted AUD$800,000 in venture capital and grants to develop drugs that could displace aspirin in long-term prevention and treatment of cardiovascular disease.
US backs down on health IP
22 July, 2003 by Jeremy TorrStrong negative reaction from local industry bodies has led to the US modifying plans to snare biotech IP by funding grants to Australian researchers.
Meditech starts anti-cancer clinical trial
15 July, 2003 by Jeremy TorrMeditech Research is to start clinical trials on its HyCAMP anti-cancer compound, targeting colorectal tumours in patients at the Centre for the Development of Cancer Therapeutics in Melbourne.
Bionomics takes a bite of Big Apple bank
14 July, 2003 by Melissa TrudingerBionomics has entered into a standby equity facility with an affiliate of the Bank of New York, allowing the company to sell up to six million shares through the affiliate group over the next three years.
Pathologists back down from GTG attack
11 July, 2003 by Melissa TrudingerThe Royal College of Pathologists of Australasia (RCPA) and associated genetics organisations, including the Human Genetics Society of Australia, have retracted and clarified recent statements made in a letter to state and Federal government officials, which suggested that Melbourne biotech company Genetic Technologies would seek to enforce the breast cancer gene patents licensed to it by Myriad Genetics.
Benefits outweigh gene therapy risks
09 July, 2003 by Melissa TrudingerThe risks of developing cancer as a side-effect of gene therapy were outweighed by the potential benefit to the patients, one of the scientists involved in gene therapy clinical trials said yesterday at the XIX International Congress of Genetics.
Panbio scores FDA approval, world first
09 July, 2003 by Jeremy TorrBribane diagnostic biotech Panbio has become the first company ever to rate US FDA approval for a West Nile virus (WNV) immunoassay diagnostic kit.
BioFirst lures researchers
09 July, 2003 by Jeremy TorrNSW’s BioFirst awards have attracted two top overseas researchers to the state, in the first of this year’s appointments for overseas experts.
Mouse model could ID mental illness gene
09 July, 2003 by Melissa TrudingerA schizophrenic mouse model has led the way to identification of a gene potentially predisposing humans to the devastating human mental illness.
Huntington's test tale proves our unpredictability
08 July, 2003 by Graeme O'NeillWithin a year of the identification in 1993 of the huntingtin gene, which in mutant form causes the fatal brain disorder Huntington's disease, geneticists devised a test to detect the mutation, and offered it to families with a history of the disease.
Granny off the hook in menopause mystery
07 July, 2003 by Graeme O'NeillGeneticists appear to have failed in their latest attempt to indict human grandmothers in the court of life for indirectly visiting menopause upon their daughters.
Garvan reaps surprise windfall
20 June, 2003 by Jeremy TorrThe Garvan Institute celebrated 40 years of sharp end research into cancer and associated diseases last week -- and in the process gained over $1million in research funds.
Norwood Abbey planning clinical trial
19 June, 2003 by Melissa TrudingerNorwood Abbey is in the midst of planning an international clinical trial examining the use of its Gonadotropin Releasing Hormone (GnRH) analogue drugs to revive the immune system in patients with HIV/AIDS.
Aust HIV vaccine trial now recruiting subjects
06 June, 2003 by Jeremy TorrThe first HIV vaccine developed in Australia is expected to go to clinical trials within months, with results expected in mid 2004.
Woolcock, Hunter join forces in sleep research network
04 June, 2003 by Susan WilliamsonThe Woolcock Institute of Medical Research in Sydney and the Hunter Medical Research Institute (HMRI) in Newcastle have joined forces to form what they claim is the largest respiratory and sleep research network in the southern hemisphere.
